Treatment Of Post-Keratoplasty Epithelial Defects With Autologous Platelet-Rich Plasma
Published 2023 - 41st Congress of the ESCRS
Reference: PO0737 | Type: Free paper | DOI: 10.82333/cs2s-6t71
Authors: Amr El Aswad* 1 , jorge alio 2 , Alejandra E. Rodriguez 3 , Alejandra E. Rodriguez 3 , Dominika Wróbel-Dudzińska 3 , mehany korashy 4
1anterior segment,cairo international eye hospital,cairo,Egypt;refractive/cornea,research institute of ophthalmology,cairo,Egypt, 2refractive/cornea,vissum,alicante,Spain;refractive,UMH,elche,Spain, 3cornea,vissum,alicante,Spain, 4refractive/cornea,RIO,cairo,Egypt
Purpose
To assess the efficacy and safety of autologous eye platelet rich plasma eye drops as an exclusive treatment to Post-keratoplasty epithelial defects
Setting
Cairo International Eye Hospital, Cairo, Egypt
Methods
117 patients with post-keratoplasty epithelial defects were enrolled. 97 patients had undergone manual keratoplasty while 20 patients underwent Femtosecond assisted keratoplasty. Previous treatments were stopped 48 hours before starting the E-PRP treatment. Patients were treated with topical autologous E-PRP eye drops 6 times a day and followed up for 6 weeks. Main outcome measures were to assess the increase in best spectacle corrected visual acuity as measured by Snellen charts, decrease in fluorescein staining and observation of the symptoms after treatment.
Results
88 % of patients of improved at least 1 line of best corrected visual acuity. Subjective symptoms improved in 96 % of the cases. A decrease or disappearance of corneal fluorescein staining was observed in 92 % of the patients.
Conclusions
Autologous eye-platelet-rich plasma confirmed to be an effective and safe therapy in the treatment of post-surgical epithelial defect.